Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:BSX 30 December 2025 - 10 February 2026

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific shares rose 0.7% to $74.61 by early afternoon Tuesday after a 2.8% drop Monday. New four-year Farapulse data showed higher treatment success than thermal ablation, with no long-term safety issues. Around 9.1 million shares traded by 1:15 p.m. The next major update is expected from the CHAMPION-AF trial results at ACC.26 on March 28.
10 February 2026
··
Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific shares slipped 0.2% to $77.49 in late-morning trading Friday, lagging a broader market rally. The stock remains under pressure after its electrophysiology segment missed sales estimates in the fourth quarter, triggering its steepest drop in over 25 years. Investors are watching for signs management can meet first-quarter growth targets. Trading volume stayed elevated as analysts revised forecasts.
6 February 2026
·
Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific shares rose 1.7% to $94.12 Monday, outpacing medical-device peers and the S&P 500. Evercore reaffirmed its Outperform rating and $112 target, dismissing concerns about the $14.5 billion Penumbra acquisition. Investors await the Feb. 4 earnings call for updates on integration, financing, and demand trends. The Penumbra deal is expected to close in 2026.
26 January 2026
··

Stock Market Today

  • Premier Investments Halves Decline with Steady Profits, Dividend Boost
    March 20, 2026, 1:30 AM EDT. Premier Investments reported steady first-half profits of nearly $102 million despite softer sales. Total revenue rose 3% to about $480 million, but Smiggle's sales fell amid weak discretionary spending and rising interest rates squeezing younger consumers. The company declared a fully franked interim dividend of 45 cents per share, contrasting with no payout last year. Premier's share price gained on dividend news and a share buyback plan. Facing market challenges, the retailer is restructuring Smiggle to better appeal to children aged 6 to 12 and benefits from its stake in Breville Group, enhancing diversification. Investors remain watchful for potential acquisitions supported by Premier's strong balance sheet.
Go toTop